Sie können Operatoren mit Ihrer Suchanfrage kombinieren, um diese noch präziser einzugrenzen. Klicken Sie auf den Suchoperator, um eine Erklärung seiner Funktionsweise anzuzeigen.
Findet Dokumente, in denen beide Begriffe in beliebiger Reihenfolge innerhalb von maximal n Worten zueinander stehen. Empfehlung: Wählen Sie zwischen 15 und 30 als maximale Wortanzahl (z.B. NEAR(hybrid, antrieb, 20)).
Findet Dokumente, in denen der Begriff in Wortvarianten vorkommt, wobei diese VOR, HINTER oder VOR und HINTER dem Suchbegriff anschließen können (z.B., leichtbau*, *leichtbau, *leichtbau*).
Although dipstick urinalysis has been widely used as part of health screening for employees, its efficacy in predicting renal function decline in healthy workers has not been elucidated.
Methods
We conducted a 10-year follow-up study of 33,139 Japanese healthy workers to determine the association between dipstick urinalysis results (urinary protein levels) and the development of adverse kidney outcomes (rapid eGFR decline and low eGFR) and to assess the predictive accuracy of dipstick urinalysis for the 10-year incidence of adverse kidney outcomes.
Results
Trace (±) and positive (1+, 2+, and 3+) dipstick proteinuria were found in 2.8% and 0.8% of the total, respectively. They had a significantly increased risk of adverse kidney outcomes than those who were negative. The sensitivity of dipstick urinalysis to discriminate between those with and without adverse kidney outcomes within 10 years was extremely low (0.01–0.07), while its specificity was nearly perfect (0.97–1.00). The sensitivity and specificity were robust to varying cutoffs (± or 1+) and to testing once or twice.
Conclusion
Workers who have at least one trace or positive result on dipstick urinalysis are more likely to have declining renal function within 10 years than those who do not. The specificity of almost 1.0 suggests that this noninvasive, inexpensive test will not miss workers whose renal function is expected to decline within the next 10 years. Occupational health staff should compile a list of workers with trace and positive results and ensure that those on the list take the necessary actions, such as retests and hospital visits, in a timely manner.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Introduction
Chronic kidney disease (CKD), which ranks among the top 10 causes of death in the United States [1] and Japan [2], is known to increase the risk of cardiovascular disease as well as progress to renal failure (end-stage kidney disease; ESKD) [3]. Although most CKD patients are asymptomatic, early detection is required [4]. Dipstick urinalysis has been used for more than 50 years as an initial screening tool to detect proteinuria, because it is noninvasive, low cost, widely available, and provides rapid results. Despite its shortcomings, [5] dipstick urinalysis applied to mass screening for public health purposes has contributed to reducing disparities in accessibility to healthcare services.
In Japan, the Occupational Health and Safety Law requires annual health examinations for employees, and one of the test items includes urinary dipstick protein. Screening for proteinuria is important for workers, because occupational exposure to toxic substances, as well as hypertension and diabetes, can cause kidney damage. However, urinary dipstick protein is often overlooked because of its low prevalence compared to hypertension, hyperglycemia, and dyslipidemia: According to the latest statistics reported by the Ministry of Health, Labour, and Welfare, the percentages of workers with hypertension, hyperglycemia, and dyslipidemia were 18.3%, 31.2%, and 13.1%, respectively, compared to 3.8% for urinary dipstick protein.[6]
Anzeige
The presence of proteinuria predicts future decline in renal function [7]. Several studies have been conducted on the efficacy of dipstick urinalysis in the general population, [8, 9] but no attempts to evaluate it in a working population have been reported to date. It is well known that the ‘healthy worker effect’ phenomenon is observed in studies of workers: The incidence of health problems among workers is not comparable to that of the general population, because current workers are much healthier than community residents [10]. Because of the lower incidence of health problems, the predictive ability of dipstick urinalysis for adverse kidney outcomes in healthy workers may not be necessarily equivalent to that in the general population. Nor has it been determined what the optimal cutoff of the test is for screening workers at high risk of future decline in renal function.
Using annual health examination data from 2013 to 2023, we conducted a 10-year follow-up study to determine whether dipstick urinalysis results are predictive of adverse kidney outcomes in healthy workers. Since the occurrence of ESKD is extremely rare among workers, [11] a decrease in estimated glomerular filtration rate (eGFR) was followed as a surrogate outcome [12].
Methods
Participants
Electronic data of the annual health examination for employees were collected from the Tokyo Health Service Association, which provides health examinations to 130,000 employees of 1400 companies in the Tokyo metropolitan area every year. Each examinee is given a unique identifier number as a means of managing his/her health examination data. The annual health examination data can be combined by a one-to-one merge based on the identifier number. The study protocol was approved by the ethics committee of the Tokyo Health Service Association (R6-6) and has been conducted in accordance with the Ethical Guidelines for Medical and Biological Research Involving Human Subjects by the Japanese Government and the Helsinki declaration.
Figure 1 shows the flow diagram of sample selection. The cohort dataset for this study was constructed using annual health examination data from 2013 to 2023. Eligible participants were Japanese healthy workers aged 25–64 years with health examination data for 2013 and 2014 and at least one follow-up between 2015 and 2023. Those with an eGFR of less than 45 mL/min/1.73 m2 at baseline and those with any renal or cardiovascular disease under treatment were excluded. Finally, 33,139 people were included in the analysis.
Annual health examination for employees, including anthropometric measurements, laboratory tests, and a self-administered questionnaire, was performed in compliance with the Industrial Safety and Health Act and its related regulations. Blood pressure was measured with an electronic sphygmomanometer with the participant sitting in a chair after at least 5 min of rest; if it exceeded 130/85 mmHg, blood pressure was measured again after another 5 min of rest. The lower measured value was adopted as the participant’s blood pressure. Blood (collected on an empty stomach) and urine (collected as midstream urine) samples were taken on arrival at the health examination site. All samples were immediately assayed at the laboratory of the Tokyo Health Service Association, where both internal and external quality controls of laboratory data are routinely performed in accordance with established guidelines. Dipstick proteinuria was assessed by an automated reader and recorded on five levels (–, ±, 1+, 2+, and 3+). Trace (±), 1+, 2+, and 3+ mean that the urine contains 15 mg/dL, 30 mg/dL, 100 mg/dL, and 300 mg/dL or more protein, respectively. eGFR was calculated from serum creatinine (Cr) using the equation for Japanese adults: eGFR (mL/min/1.73 m2)=194×Cr (mg/dl)–1.094×age–0.287×0.739 (if female).[13]
The occurrence of two changes in eGFR, ‘rapid eGFR decline’ and ‘low eGFR’, were followed as adverse kidney outcomes. ‘Rapid eGFR decline’ was defined as a consistent decline in eGFR with the rate of decline exceeding 5 mL/min/1.73 m2 per year in any year during the follow-up period.[14, 15] Those whose eGFR temporarily declined or fluctuated were not counted as cases. ‘Low eGFR’ was defined as eGFR falling to 45 mL/min/1.73 m2 (equivalent to CKD KDIGO stages G3b-5) and remaining below 45 mL/min/1.73 m2 thereafter.3 Those whose eGFR temporarily reached 45 mL/min/1.73 m2 and then improved were not counted as cases.
Hypertension was defined as systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg and/or taking medication.[16] Hyperglycemia was defined as fasting blood glucose ≥126 mg/dL (7.0 mmol/L) and/or random plasma glucose ≥200 mg/dL (11.0 mmol/L) and/or hemoglobin A1c ≥6.5 % and/or taking medication.[17] Anemia was defined as hemoglobin <13 g/dL in male and <12 g/dL in female.[18]
Statistical analysis
All statistical analyses were performed using the SAS ver. 9.4 (SAS Institute, Cary, NC, USA). Significant levels were set at p <0.05. Kaplan–Meier analysis with log-rank test was performed to compare the incidence of adverse kidney outcomes over 10 years. Cox proportional hazard models were used to determine the association between dipstick urinalysis results and the development of adverse kidney outcomes. Hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated with adjustment for gender, age, hypertension, hyperglycemia, anemia, and eGFR at baseline. The predictive accuracy of dipstick urinalysis for the 10-year incidence of adverse kidney outcomes was assessed by sensitivity (i.e., the proportion of those with adverse kidney outcomes who are correctly identified by the test), specificity (i.e., the proportion of those without adverse kidney outcomes who are correctly excluded by the test), positive predictive value (i.e., the proportion of those with a positive test result who truly have an adverse kidney outcome), negative predictive value (i.e., the proportion of those with a negative test result who truly do not have an adverse kidney outcome), and likelihood ratios for four different combinations of cutoff (±, or 1+) and number of tests (baseline only, or baseline and the following year) [19].
Results
Table 1 shows the baseline characteristics of the study population. Most (96.3%) of the participants were negative for dipstick proteinuria and had an eGFR of at least 60 mL/min/1.73 m2. Table 2 shows the comparison of baseline characteristics by urinary protein level. Due to the large sample size, statistically significant differences (p<0.05) were observed for most of the items listed in the table. Those who were overweight (BMI ≥25.0), had hypertension, diabetes, anemia, or smoked tended to have higher urinary protein levels.
Table 1
Baseline characteristics of the study population (Japanese workers aged 25–64 years, n=33,139)
N
Gender
Men
22,517
67.9%
Women
10,622
32.1%
Age, years
<40
12,467
37.6%
40≤
20,672
62.4%
Body mass index
≤18.5
2,724
8.2%
18.6–24.9
22,644
68.3%
25.0≤
7771
23.4%
Hypertension
4946
14.9%
Hypertension level
3160
9.5%
Antihypertensive medication
2587
7.8%
Diabetes
1345
4.1%
Diabetes level
1249
3.8%
Antidiabetic medication
745
2.2%
Anemia
1979
6.0%
eGFR, mL/min/1.73 m2
60≤
31,890
96.2%
45–59
1249
3.8%
Urinary protein
‒
31,925
96.3%
±
942
2.8%
1+
171
0.5%
2+≤
101
0.3%
Smoking habits
Non-smoker
15,889
47.9%
Ex-smoker
4218
12.7%
Smoker
6819
20.6%
Unknown
6213
18.7%
Hypertension was defined as having a hypertension level (systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg) and/or taking antihypertensive medication. Diabetes was defined as having a diabetes level (fasting blood glucose ≥126 mg/dL (7.0 mmol/L) and/or random plasma glucose ≥200 mg/dL (11.0 mmol/L) and/or hemoglobin A1c ≥6.5 %) and/or taking antidiabetic medication. Anemia was defined as hemoglobin <13 g/dL in men and <12 g/dL in women.
eGFR estimated glomerular filtration rate
Table 2
Comparison of baseline characteristics by urinary protein level
Urinary protein
‒
N
±
N
1+
N
2+≤
N
p
Gender
Men
21,707
96.4%
620
2.8%
114
0.5%
76
0.3%
0.204
Women
10,218
96.2%
322
3.0%
57
0.5%
25
0.2%
Age, years
<40
12,046
96.6%
340
2.7%
48
0.4%
33
0.3%
0.032
40≤
19,879
96.2%
602
2.9%
123
0.6%
68
0.3%
Body mass index
≤18.5
2,626
96.4%
77
2.8%
14
0.5%
7
0.3%
<0.001
18.6–24.9
21,996
97.1%
521
2.3%
87
0.4%
40
0.2%
25.0≤
7303
94.0%
344
4.4%
70
0.9%
54
0.7%
Hypertension
No
27,368
97.1%
676
2.4%
95
0.3%
54
0.2%
<0.001
Yes
4557
92.1%
266
5.4%
76
1.5%
47
1.0%
Hypertension level
No
29,008
96.8%
776
2.6%
127
0.4%
68
0.2%
<0.001
Yes
2917
92.3%
166
5.3%
44
1.4%
33
1.0%
Antihypertensive medication
No
29,589
96.8%
771
2.5%
122
0.4%
70
0.2%
<0.001
Yes
2336
90.3%
171
6.6%
49
1.9%
31
1.2%
Diabetes
No
30,758
96.7%
817
2.6%
143
0.4%
76
0.2%
<0.001
Yes
1167
86.8%
125
9.3%
28
2.1%
25
1.9%
Hypertension level
No
30,846
96.7%
823
2.6%
144
0.5%
77
0.2%
<0.001
Yes
1079
86.4%
119
9.5%
27
2.2%
24
1.9%
Antihypertensive medication
No
31,303
96.6%
857
2.6%
154
0.5%
80
0.2%
<0.001
Yes
622
83.5%
85
11.4%
17
2.3%
21
2.8%
Anemia
No
30,045
96.4%
875
2.8%
151
0.5%
89
0.3%
<0.001
Yes
1880
95.0%
67
3.4%
20
1.0%
12
0.6%
eGFR, mL/min/1.73 m2
60≤
30,779
96.5%
873
2.7%
151
0.5%
87
0.3%
<0.001
45–59
1146
91.8%
69
5.5%
20
1.6%
14
1.1%
Smoking habits
Non-smoker
15,325
96.5%
450
2.8%
80
0.5%
34
0.2%
<0.001
Ex-smoker
4075
96.6%
104
2.5%
27
0.6%
12
0.3%
Smoker
6386
93.7%
254
3.7%
40
0.6%
39
0.6%
Unknown
6039
97.2%
134
2.2%
24
0.4%
16
0.3%
Hypertension was defined as having a hypertension level (systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg) and/or taking antihypertensive medication. Diabetes was defined as having a diabetes level (fasting blood glucose ≥126 mg/dL (7.0 mmol/L) and/or random plasma glucose ≥200 mg/dL (11.0 mmol/L) and/or hemoglobin A1c ≥6.5 %) and/or taking antidiabetic medication. Anemia was defined as hemoglobin <13 g/dL in men and <12 g/dL in women.
eGFR estimated glomerular filtration rate
During the follow-up period, rapid eGFR decline was observed in 2,059 people (6.2%) and low eGFR in 214 people (0.6%), with 190 people (0.6%) developing both. The Kaplan–Meier analysis (Fig. 2) showed that the incidence of adverse kidney outcomes increased significantly with higher urinary protein levels (p<0.001). Similar results were obtained when the two adverse kidney outcomes were analyzed separately. As shown in Table 3 (a), after adjusting for plausible confounders, higher levels of urinary protein at baseline were more strongly associated with the development of adverse kidney outcomes. This association was more pronounced for low eGFR than for rapid eGFR decline.
Fig. 2
Kaplan–Meier curves for incidence of adverse kidney outcomes by urinary protein level at baseline. Participants were divided into four groups according to the dipstick urinalysis result at baseline (–, ±, 1+, and 2+≤). Adverse kidney outcomes were rapid eGFR decline (defined as eGFR slope <− 5 mL/min/1.73 m2 per year) and low eGFR (defined as eGFR <45 mL/min/1.73 m2). eGFR: estimated glomerular filtration rate
Hazard ratios for the development of adverse kidney outcomes over 10 years (Japanese workers aged 25–64 years, n=33,139)
Rapid eGFR decline or low eGFR
Rapid eGFR decline
Low eGFR
Incidence/Total
HR (95%CI)
Incidence/Total
HR (95%CI)
Incidence/Total
HR (95%CI)
(a) Dipstick urinalysis result at baseline
–
1,897/31,925
1.00
(reference)
1,877/31,925
1.00
(reference)
1,607/31,925
1.00
(reference)
±
116/942
1.77
(1.45–2.13)
114/942
1.81
(1.48–2.18)
26/942
2.94
(1.86–4.47)
1+
38/171
2.77
(1.97–3.77)
36/171
2.67
(1.88–3.66)
10/171
5.99
(2.94–10.86)
2+≤
32/101
3.97
(2.73–5.54)
32/101
4.52
(3.11–6.31)
18/101
19.08
(11.14–30.81)
(b) Dipstick urinalysis results at baseline and the following year
Persistent negative (‒→‒)
1,823/31,188
1.00
(reference)
1,805/31,188
1.00
(reference)
145/31,188
1.00
(reference)
Transient trace (± → ‒ or ‒ → ±)
121/1,282
1.71
(1.41–2.05)
118/1282
1.70
(1.40–2.04)
23/1282
3.41
(2.13–5.22)
Transient positive (1+≤ → ‒ or ‒ → 1+≤)
26/224
1.77
(1.17–2.55)
25/224
1.72
(1.12–2.49)
5/224
2.76
(0.96–6.20)
Persistent trace (± → ±)
32/215
1.41
(0.97–1.98)
31/215
1.47
(1.00–2.06)
9/215
2.44
(1.13–4.62)
Positive to trace (1+≤ → ±)
12/60
2.11
(1.13–3.56)
12/60
2.29
(1.22–3.86)
4/60
5.14
(1.57–12.34)
Trace to positive (± → 1+≤)
25/78
3.05
(2.00–4.45)
25/78
(2.21–4.93)
7/78
5.02
(2.09–10.17)
Persistent positive (1+≤ → 1+≤)
44/92
6.01
(4.36–8.06)
43/92
6.56
(4.74–8.80)
21/92
25.52
(15.30–40.64)
HRs and 95% CIs were calculated with a Cox proportional hazard model adjusted for gender, age, hypertension, diabetes, anemia, and eGFR at baseline. Rapid eGFR decline was defined as eGFR slope <− 5 mL/min/1.73 m2 per year. Low eGFR was defined as eGFR <45 mL/min/1.73 m2.
Dipstick urinalysis results can be affected by the concentration and pH of the urine[20]. In fact, the urinary protein levels at baseline changed in the following year’s health examination for many participants. Of the 942 people who were trace (±) at baseline, 649 (68.9%) turned negative at the following year. Of the 271 people who were positive (1+, 2+, and 3+) at baseline, 120 (44.1%) and 60 (22.1%) turned negative and trace (±), respectively at the following year. Participants were divided into six groups according to a combination of dipstick urinalysis results at baseline and the following year (persistent negative, transient trace, transient positive, persistent trace, positive to trace, trace to positive, and persistent positive), and the incidence of adverse kidney outcomes was compared between groups. The Kaplan–Meier analysis (Fig. 3) showed that the incidence of adverse kidney outcomes was higher in the four groups with at least one positive result (transient positive, positive to trace, trace to positive, and persistent positive) and highest in the persistent positive group (p<0.001). Similar results were obtained when the two adverse kidney outcomes were analyzed separately. As shown in Table 3 (b), after adjusting for plausible confounders, all groups with at least one trace (±) or positive result had a significantly increased risk of adverse kidney outcomes than the persistent negative group.
Fig. 3
Kaplan–Meier curves for incidence of adverse kidney outcomes by urinary protein level at baseline and the following year. Participants were divided into six groups according to a combination of dipstick urinalysis results at baseline and the following year (persistent negative, transient trace, transient positive, persistent trace, positive to trace, trace to positive, and persistent positive). Adverse kidney outcomes were rapid eGFR decline (defined as eGFR slope <− 5 mL/min/1.73 m2 per year) and low eGFR (defined as eGFR <45 mL/min/1.73 m2). eGFR: estimated glomerular filtration rate.
The predictive accuracy of dipstick urinalysis for the 10-year incidence of adverse kidney outcomes was evaluated in 14,161 people with complete 10-year follow-up data. When judged by one test result (at baseline), 442 people (3.1%) had trace (±) or greater, of which 100 (0.7%) had 1+ or greater. The sensitivity and specificity to discriminate between those with and without adverse kidney outcomes within 10 years were 0.07 (85/1,136) and 0.97 (12,668/13,025), respectively, using trace (±) as the cutoff, and were 0.02 (27/1,136) and 0.99 (12,952/13,025), respectively, using 1+ as the cutoff. The positive and negative predictive values were 0.19 (89/442) and 0.92 (12,668/13,719), respectively, using trace (±) as the cutoff, and were 0.27 (27/100) and 0.92 (12,952/14,061), respectively, using 1+ as the cutoff.
Anzeige
When judged by two test results (at baseline and the following year), 167 people (1.2%) were both trace (±) or greater, of which 36 (0.3%) were both 1+ or greater. The sensitivity and specificity to discriminate between those with and without adverse kidney outcomes within 10 years were 0.05 (53/1,136) and 0.99 (12,911/13,025), respectively, using trace (±) as the cutoff, and were 0.01 (17/1,136) and 1.00 (13,006/13,025), respectively, using 1+ as the cutoff. The positive and negative predictive values were 0.32 (52/167) and 0.92 (12,911/13,994), respectively, using trace (±) as the cutoff, and were 0.47 (17/36) and 0.92 (13,006/14,125), respectively, using 1+ as the cutoff. The positive likelihood ratio ranged from 2.7 (minimum) when using a single test result with a cutoff of trace (±) to 10.3 (maximum) when using two test results with a cutoff of +1. The negative likelihood ratio ranged from 0.95 (minimum) when using a single test result with a cutoff of trace (±) to 0.99 (maximum) when using two test results with a cutoff of +1.
Discussion
Although dipstick urinalysis has long been part of the annual health examination for employees in Japan, its efficacy in predicting renal function decline in healthy workers has not been elucidated. Recently, the Japanese CKD guidelines have revised the handling of dipstick urinalysis results, recommending that even a trace (±) level of urinary protein should not be left unattended: Health examinees with a trace (±) result are advised to improve their lifestyle, and if a trace (±) or positive result is found again in the next year’s health examination, they should be encouraged to seek medical consultation [21]. However, to our knowledge, there has been no epidemiological evidence to support the validity of this approach among workers. We conducted a 10-year follow-up study of 33,139 Japanese healthy workers to determine the association between dipstick urinalysis results and the development of adverse kidney outcomes (rapid eGFR decline and low eGFR) and to assess the predictive accuracy of dipstick urinalysis for the 10-year incidence of adverse kidney outcomes.
Although only a few percent of the total had trace (±) and positive dipstick proteinuria, they had a significantly increased risk of adverse kidney outcomes than those who were negative. When analyzing the dipstick urinalysis results of two consecutive years to address possible variability in dipstick urinalysis results, the risk of adverse kidney outcomes was significantly higher in the groups with at least one trace (±) or positive result than in the persistent negative group. These results support the latest guideline recommendation on how to handle health examinees with trace (±) results [21]. Previous follow-up studies of the general population revealed that trace (±) proteinuria, as well as positive proteinuria, was significantly associated with incident cardiovascular events (heart failure, myocardial infarction, stroke, and atrial fibrillation) and all-cause mortality [22, 23]. We must alert occupational health professionals to the need to compile a list of workers with trace (±) and positive dipstick proteinuria to manage their health risks. Occupational health staff should ensure that those on the list take the necessary actions, such as retests and hospital visits, in a timely manner.
The sensitivity of dipstick urinalysis to discriminate between those with and without adverse kidney outcomes within 10 years was extremely low (0.01–0.07), while its specificity was nearly perfect (0.97–1.00). The high specificity and low sensitivity in this study support the results of previous cross-sectional studies of the general population [5, 8, 24]. The sensitivity and specificity were robust to varying cutoffs (± or 1+) and to testing once or twice, which may represent a limitation of the dipstick urinalysis itself. However, at this time, there is no noninvasive, inexpensive CKD screening tool comparable to dipstick urinalysis. A previous cost-effectiveness study indicated that mass screening with dipstick urinalysis is an acceptable population strategy for CKD detection [25]. The specificity of almost 1 suggests that the test will not miss workers whose renal function is expected to decline within the next 10 years. The positive likelihood ratio of more than 10 using two test results with a cutoff of +1 suggests that workers with two positive results will certainly experience renal function decline if not treated [19]. The warning signs of declining renal function should not be overlooked to prevent more serious consequences, such as ESKD and cardiovascular diseases.
Anzeige
This study is the first to report the efficacy of screening with dipstick urinalysis in predicting renal function decline in healthy workers. The results of this study indicated an optimal dipstick urinalysis cutoff for screening workers at high risk of future decline in renal function and confirmed the need to manage the health risks of workers who exceed the cutoff. On the contrary, it has the following potential limitations. First, the study participants were selected from employees who received annual health examinations at the Tokyo Health Service Association. Of these, those who never had a health examination between 2015 and 2023 were excluded from the study. The selection bias may have some influence on the results. Second, information on treatment was collected in the questionnaire, but the type of medication used was not asked. Some medications are known to affect urinary protein (such as RAS inhibitors and SGLT2 inhibitors) and eGFR (such as diuretics and NSAIDs). The results of this study may have been influenced in some way by the use of medication. Third, the effect of socioeconomic status was not adjusted for in the analysis of the association between dipstick urinalysis results and the development of adverse kidney outcomes, because this information was not collected in the annual health examination for employees. However, the majority of the study population were office workers in the Tokyo metropolitan area, who are likely to have much smaller socioeconomic disparities than the general population. Since the participants were not sampled to be representative of the Japanese working population, caution should be exercised when applying the results of this study to Japan as a whole. The incidence, prevalence, and progression of CKD vary by country and ethnicity [3]. Further studies are needed to confirm whether the findings of this study are applicable to other country populations.
Conclusion
Screening with dipstick urinalysis provides useful information for predicting future decline in renal function in healthy workers. Those who have at least one trace (±) or positive result on dipstick urinalysis are more likely to have declining renal function within 10 years than those who do not. The specificity of almost 1 suggests that this noninvasive, inexpensive test will not miss workers whose renal function is expected to decline within the next 10 years. Occupational health staff should compile a list of workers with trace (±) and positive results and ensure that those on the list take the necessary actions, such as retests and hospital visits, in a timely manner. Dipstick urinalysis results can also be used as a trigger to initiate lifestyle modifications, work environment improvements, and control of risk factors such as hypertension and diabetes, thereby increasing the likelihood that workers will continue to work in good health.
Acknowledgements
The authors are grateful to Dr Mie Kawai and the staff of Tokyo Health Service Association for their help in data collection.
Declarations
Conflict of interest
The authors declare no potential conflicts of interest with respect to the research, authorship, or publication of this article.
Anzeige
Research involving human and animals participants
The study protocol was approved by the ethics committee of the Tokyo Health Service Association (R6-6) and has been conducted in accordance with the Ethical Guidelines for Medical and Biological Research Involving Human Subjects by the Japanese Government and the Helsinki declaration.
Informed consent
The Tokyo Health Service Association obtained written informed consent from health examinees to use their health examination data for research purposes under conditions of anonymity and confidentiality.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Levin A, Okpechi IG, Caskey FJ, Yang CW, Tonelli M, Jha V. Perspectives on early detection of chronic kidney disease: the facts, the questions, and a proposed framework for 2023 and beyond. Kidney Int. 2023;103:1004–8.CrossRefPubMed
5.
Samal L, Linder JA. The primary care perspective on routine urine dipstick screening to identify patients with albuminuria. Clin J Am Soc Nephrol. 2013;8:131–5.CrossRefPubMed
Cravedi P, Remuzzi G. Pathophysiology of proteinuria and its value as an outcome measure in chronic kidney disease. Br J Clin Pharmacol. 2013;76:516–23.CrossRefPubMedPubMedCentral
8.
Clark WF, Macnab JJ, Sontrop JM, Jain AK, Moist L, Salvadori M, Suri R, Garg AX. Dipstick proteinuria as a screening strategy to identify rapid renal decline. J Am Soc Nephrol. 2011;22:1729–36.CrossRefPubMedPubMedCentral
9.
Koeda Y, Tanaka F, Segawa T, Ohta M, Ohsawa M, Tanno K, Makita S, Ishibashi Y, Itai K, Omama SI, Onoda T, Sakata K, Ogasawara K, Okayama A, Nakamura M. Comparison between urine albumin-to-creatinine ratio and urine protein dipstick testing for prevalence and ability to predict the risk for chronic kidney disease in the general population (Iwate-KENCO study): a prospective community-based cohort study. BMC Nephrol. 2016;17:46.CrossRefPubMedPubMedCentral
10.
Li CY, Sung FC. A review of the healthy worker effect in occupational epidemiology. Occup Med (Lond). 1999;49:225–9.CrossRefPubMed
11.
Noborisaka Y, Ishizaki M, Yamada Y, Honda R, Yokoyama H, Miyao M, Tabata M. Distribution of and factors contributing to chronic kidney disease in a middle-aged working population. Environ Health Prev Med. 2013;18:466–76.CrossRefPubMedPubMedCentral
12.
Abenavoli C, Provenzano M, Ksiazek SH, Hu L, Cuna V, Manna G, Comai G, Baraldi O. Role of estimated glomerular filtration rate in clinical research: the never-ending matter. Rev Cardiovasc Med. 2024;25:1.CrossRefPubMedPubMedCentral
13.
Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53(6):982–92.CrossRefPubMed
14.
Go AS, Yang J, Tan TC, Cabrera CS, Stefansson BV, Greasley PJ, Ordonez JD. Contemporary rates and predictors of fast progression of chronic kidney disease in adults with and without diabetes mellitus. BMC Nephrol. 2018;19:146.CrossRefPubMedPubMedCentral
15.
Heerspink H, Nolan S, Carrero JJ, Arnold M, Pecoits-Filho R, García Sánchez JJ, Wittbrodt E, Cabrera C, Lam CSP, Chen H, Kanda E, Lainscak M, Pollock C, Wheeler DC. Clinical outcomes in patients with CKD and rapid or non-rapid eGFR decline: a report from the DISCOVER CKD Retrospective Cohort. Adv Ther. 2024;41:3264–77.CrossRefPubMedPubMedCentral
16.
Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D, Ramirez A, Schlaich M, Stergiou GS, Tomaszewski M, Wainford RD, Williams B, Schutte AE. 2020 International Society of Hypertension global hypertension practice guidelines. Hypertension. 2020;75:1334–57.CrossRefPubMed
Viswanathan G, Upadhyay A. Assessment of proteinuria. Adv Chronic Kidney Dis. 2011;18:243–8.CrossRefPubMed
21.
Japanese Society of Nephrology. Evidence-based clinical practice guideline for CKD 2023 (in Japanese). https://jsn.or.jp/medic/guideline/ (Access at May 1, 2025)
22.
Sato H, Konta T, Ichikawa K, Suzuki N, Kabasawa A, Suzuki K, Hirayama A, Shibata Y, Watanabe T, Kato T, Ueno Y, Kayama T, Kubota I. Comparison of the predictive ability of albuminuria and dipstick proteinuria for mortality in the Japanese population: the Yamagata (Takahata) study. Clin Exp Nephrol. 2016;20:611–7.CrossRefPubMed
23.
Fukui A, Kaneko H, Okada A, Yano Y, Itoh H, Matsuoka S, Morita K, Kiriyama H, Kamon T, Fujiu K, Michihata N, Jo T, Takeda N, Morita H, Nakamura S, Nishiyama A, Node K, Yokoo T, Nangaku M, Yasunaga H, Komuro I. Semiquantitative assessed proteinuria and risk of heart failure: analysis of a nationwide epidemiological database. Nephrol Dial Transplant. 2022;37:1691–9.CrossRefPubMed
24.
White SL, Yu R, Craig JC, Polkinghorne KR, Atkins RC, Chadban SJ. Diagnostic accuracy of urine dipsticks for detection of albuminuria in the general community. Am J Kidney Dis. 2011;58:19–28.CrossRefPubMed
25.
Kondo M, Yamagata K, Hoshi SL, Saito C, Asahi K, Moriyama T, Tsuruya K, Yoshida H, Iseki K, Watanabe T. Cost-effectiveness of chronic kidney disease mass screening test in Japan. Clin Exp Nephrol. 2012;16:279–91.CrossRefPubMed
Je höher der BMI, umso höher ist das Risiko, bei einer Infektion zu sterben. Das gilt nicht nur für Covid-19, sondern für Infektionen allgemein. Bei einer Grad-III-Adipositas ist die Mortalität während einer Infektion sogar verdreifacht. Darauf deuten Daten aus Finnland und Großbritannien.
Periphere Fazialisparesen sollten nicht vorschnell als idiopathisch klassifiziert werden. Vor allem bei atypischen Manifestationen gilt es, auf dem Quivive zu sein. Der Fall einer 73-Jährigen zeigt, warum.
Bei der Festlegung der Intervalle für Kontrollkoloskopien nach einer Polypektomie sollten nicht ausschließlich polypenbezogene Merkmale berücksichtigt werden. Wie eine internationale Studie zeigt, beeinflussen auch individuelle demografische Faktoren, wie Geschlecht, Body-Mass-Index und Ethnie, das Rezidivrisiko.
In einer Kohortenstudie wurde ein Zusammenhang zwischen oralen Bakterien und Pilzen und dem Auftreten von Pankreaskarzinomen gesehen. Diese Assoziation könnte helfen, Patientinnen und Patienten für gezielte Vorsorgeuntersuchungen ausfindig zu machen.
